Analysts Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $22.25

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $22.25.

Separately, StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd.

Insider Transactions at Aclaris Therapeutics

In other news, major shareholder Braden Michael Leonard purchased 1,000,000 shares of Aclaris Therapeutics stock in a transaction dated Tuesday, June 11th. The shares were bought at an average cost of $1.08 per share, with a total value of $1,080,000.00. Following the completion of the transaction, the insider now directly owns 10,395,934 shares in the company, valued at approximately $11,227,608.72. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have bought a total of 1,678,621 shares of company stock valued at $1,857,414 over the last three months. 6.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC raised its holdings in shares of Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 13,461 shares during the period. Corton Capital Inc. acquired a new stake in Aclaris Therapeutics in the 3rd quarter valued at $102,000. Vontobel Holding Ltd. increased its stake in Aclaris Therapeutics by 128.8% in the 4th quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 17,040 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Aclaris Therapeutics by 115.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 23,467 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Aclaris Therapeutics by 10.9% in the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after buying an additional 23,747 shares during the last quarter. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Stock Performance

Shares of ACRS opened at $1.12 on Friday. The company has a 50-day simple moving average of $1.17 and a 200-day simple moving average of $1.17. The firm has a market capitalization of $79.45 million, a P/E ratio of -1.02 and a beta of 0.06. Aclaris Therapeutics has a 52 week low of $0.59 and a 52 week high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. The business had revenue of $2.40 million during the quarter, compared to analyst estimates of $1.99 million. Aclaris Therapeutics had a negative net margin of 248.28% and a negative return on equity of 61.03%. As a group, equities analysts forecast that Aclaris Therapeutics will post -0.78 earnings per share for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.